This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (17)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Brian L. Strom, MD, MPH; Jeffrey L. Carson, MD; Rita Schinnar, MPA; Ellen Sim Snyder, MS; Michele Shaw, PharmD; Frank E. Lundin, Jr, MD, DrPH

Arch Intern Med. 1993;153(18):2119-2124.

Abstract
Background
The association between nonsteroidal anti-inflammatory drugs (NSAIDs) and neutropenia is based primarily on case reports only.

Methods
A population-based, case-control study was performed with Medicaid claims data from six states. Cases were defined as patients hospitalized with neutropenia. Four controls per case were randomly chosen, matched for age, sex, state, and year. The frequency of exposure to NSAIDs in the 30 days before hospital admission in the cases was compared with the frequency in the identical period in the controls. The diagnosis of neutropenia was validated by review of medical records.

Results
The crude odds ratio for NSAIDs as a class was 3.3 (90% confidence interval, 1.6 to 6.6). The multivariate adjusted odds ratio was 4.2 (90% confidence interval, 2.0 to 8.7). No single class of NSAIDs, nor any individual NSAID, was associated with a unique risk, although the data on individual NSAIDs were sparse. Even excluding phenylbutazone and indomethacin, an increased risk was observed (3.5 [1.6 to 7.6]).

Conclusions
Neutropenia is associated with the use of NSAIDs. However, given the low incidence of this disease, the additional number of cases of neutropenia caused by the use of NSAIDs is small. These data do not support the existence of a risk restricted to selected NSAIDs only.

(Arch Intern Med. 1993;153:2119-2124)

Author Affiliations
From the Center for Clinical Epidemiology and Biostatistics and General Internal Medicine Division, University of Pennsylvania School of Medicine, Philadelphia (Drs Strom and Carson and Mss Schinnar and Snyder); Division of General Internal Medicine, Department of Medicine, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ (Dr Carson); Department of Post-Marketing Surveillance, Health Information Designs Inc, Arlington, Va (Dr Shaw); and Division of Epidemiology and Surveillance, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md (Dr Lundin).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prostaglandin E2 Stimulates Granulocyte Colony-Stimulating Factor Production via the Prostanoid EP2 Receptor in Mouse Peritoneal Neutrophils
Sugimoto et al.
J. Immunol. 2005;175:2606-2612.
ABSTRACT | FULL TEXT  

Population-Based Drug-Induced Agranulocytosis
Ibanez et al.
Arch Intern Med 2005;165:869-874.
ABSTRACT | FULL TEXT